Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
195.7 SEK | -0.05% | +3.93% | +30.45% |
Apr. 29 | Nordic Shares Rose Monday; Ratos Series A Climbed Highest | DJ |
Apr. 26 | Nordic Shares Closed Up Friday; Medicover Series B Climbed Highest | DJ |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 56% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 1108.28 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.45% | 2.71B | B+ | ||
+18.41% | 83.94B | C+ | ||
-29.08% | 70.3B | B- | ||
+3.59% | 27.46B | C+ | ||
-7.08% | 17.8B | B | ||
+2.07% | 17.46B | A- | ||
+0.93% | 15.46B | A- | ||
+6.78% | 13.49B | B- | ||
+8.40% | 13.06B | A- | ||
+68.45% | 12.96B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MCOV B Stock
- Ratings Medicover AB